The Aussie healthtech company ResMed Inc. (NYSE:RMD) is strongly backed by institutions, owning approximately 75% of its assets. Recently, RMD has seen steady growth, trading at an overall upward trend, and seems forecasted to continue this trend into the distant future. Factors contributing to this growth include ResMed's emphasis on R&D and its strategic acquisitions, like VirtuOx. However, share selling by insiders like ResMed's CEO, Michael Farrell, has raised some concerns among investors. Nevertheless, ResMed's financial health is promising with steady revenue increases, primarily due to robust market demand, robust revenue growth,and strategic investments. The healthcare sector has been generally outperformed by RMD, thanks to a combination of Margin Expansion and Demand Generation initiatives. Despite some uncertainties around future earnings caused by competition and market forces, analysts remain largely positive about ResMed's outlook, with firms like Piper Sandler, RBC Capital, and Stifel maintaining or raising their price targets for RMD. It's also worth noting ResMed chairman emeritus' stock adjustments and the company's new investor relations hire from Illumina - suggesting strategic changes with potentially significant implications for the future.
Resmed RMD News Analytics from Tue, 27 Aug 2024 07:00:00 GMT to Sat, 05 Jul 2025 12:58:36 GMT - Rating 8 - Innovation 7 - Information 9 - Rumor 6
